The Global AI in Molecular Imaging Market was valued at USD 150.78 million in 2022 and is projected to reach USD 1,643.85 million by 2030, expanding at a CAGR of 34.8% during the forecast period (2023–2030).

AI integration into molecular imaging systems is transforming disease detection, diagnosis, and treatment planning by enabling precise visualization of biological processes at cellular and subcellular levels.

request-sample

Industry Overview

Molecular Imaging (MI) allows visualization, characterization, and quantification of biological processes inside living organisms. Unlike traditional laboratory techniques (biopsies or cell cultures), MI studies biological functions within their natural environment.

Common MI modalities include:

Positron Emission Tomography (PET)
Single-Photon Emission Computed Tomography (SPECT)
Hybrid imaging systems (PET/CT, PET/MRI)

By integrating Artificial Intelligence (AI), molecular imaging systems can:

Improve diagnostic accuracy
Reduce image noise and artifacts (deep learning reconstruction)
Automate workflows
Enhance quantitative analysis
Enable personalized treatment planning
Standardize clinical processes

AI-driven insights help clinicians make more informed and outcome-focused decisions.

Market Drivers

1️⃣ Rising Incidence of Chronic Diseases

The growing prevalence of:

Cardiovascular diseases
Neurological disorders
Cancer
Diabetes
Chronic respiratory diseases

is significantly driving demand.

AI-powered molecular imaging systems:

Detect diseases at early stages
Determine severity and metastasis
Provide non-invasive diagnostic options
Improve treatment planning

These systems deliver insights often unattainable through conventional imaging.

2️⃣ Technological Advancements in Molecular Imaging

Advanced imaging modalities generate vast and complex datasets.

AI algorithms:

Analyze high-volume imaging data efficiently
Detect subtle disease patterns
Identify correlations invisible to manual analysis
Enable faster and more precise diagnoses

This integration supports both clinical care and research innovation.

Market Challenges

High Implementation Costs

Integration requires:

Advanced hardware
AI-enabled software platforms
Skilled workforce training
Ongoing maintenance

Smaller healthcare facilities may face budget constraints.

Adoption Hesitancy

Some healthcare professionals:

Are cautious about replacing human expertise
Raise concerns about over-reliance on automation
Emphasize the importance of patient-doctor relationships

These factors may temporarily slow adoption rates.

Market Opportunities

Expansion into Emerging Healthcare Markets

Companies can benefit from:

Expanding into developing nations
Addressing gaps in healthcare infrastructure
Offering scalable AI-based imaging solutions

Growing global demand for early diagnosis creates strong commercialization potential.

COVID-19 Impact

Negative Effects

Supply chain disruptions
Manufacturing slowdowns
Workforce shortages
Deployment delays

Positive Effects

The pandemic accelerated the use of molecular imaging techniques like:

Positron Emission Tomography
Single-Photon Emission Computed Tomography

These modalities were used to study COVID-19’s impact on:

Brain function
Cardiovascular system
Other vital organs

Overall, the market experienced both disruption and innovation acceleration.

Recent Developments

In October 2022, Blue Earth Diagnostics signed a data-sharing agreement with Siemens Healthineers and the Technical University of Munich Hospital.
In June 2021, Canon Medical Systems Corporation received 510(k) clearance for its Advanced intelligent Clear-IQ Engine (AiCE) deep learning reconstruction technology on the Cartesion Prime Digital PET/CT system.

Market Segmentation

By Technology

Deep Learning
Natural Language Processing (NLP)
Others

🔹 Largest Segment (2022): Deep Learning (58.6%)

Widely used for:

Image segmentation
Object detection
Image generation
Image transformation

🔹 Fastest Growing: NLP

Increasing integration with machine learning systems is accelerating growth.

By Component

Hardware
Software
Services

🔹 Largest Segment: Software

Software solutions are preferred due to:

Easy integration into existing systems
Cost efficiency
AI-powered analytical capabilities

🔹 Fastest Growing: Services

Includes:

Training
Maintenance
Technical support

Services ensure smooth deployment and system optimization.

By Application

Cardiology
Neurology
Oncology
Others

🔹 Largest Segment: Oncology

Driven by:

Rising cancer incidence
Growing screening awareness
Increased research funding

AI improves:

Tumor detection
Treatment planning
Personalized cancer care

🔹 Fastest Growing: Cardiology

Growing need for:

Early detection of myocarditis
Atherosclerosis diagnosis
Advanced cardiac risk assessment

By End User

Hospitals
Molecular Diagnostic Laboratories
Ambulatory Surgical Centers
Medical Clinics

🔹 Largest Segment: Hospitals

Hospitals dominate due to:

Advanced infrastructure
High patient load
Availability of specialized imaging systems

🔹 Fastest Growing: Molecular Diagnostic Laboratories

Growth driven by:

Advanced imaging capabilities
Focused diagnostic specialization

BUYNOW:https://virtuemarketresearch.com/report/ai-in-molecular-imaging-market/enquire

Regional Analysis

North America (Largest Market)

Growth drivers:

High chronic disease burden
Early AI adoption
Advanced healthcare infrastructure
Strong R&D investments

Key companies headquartered here include:

Subtle Medical
Bruker Corporation
PerkinElmer
Invicro

Asia-Pacific (Fastest Growing)